Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

PURPOSE: The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METH...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Abu-Sbeih, Hamzah, Faleck, David M., Ricciuti, Biagio, Mendelsohn, Robin B., Naqash, Abdul R., Cohen, Justine V., Sellers, Maclean C., Balaji, Aanika, Ben-Betzalel, Guy, Hajir, Ibraheim, Zhang, Jiajia, Awad, Mark M., Leonardi, Giulia C., Johnson, Douglas B., Pinato, David J., Owen, Dwight H., Weiss, Sarah A., Lamberti, Giuseppe, Lythgoe, Mark P., Manuzzi, Lisa, Arnold, Christina, Qiao, Wei, Naidoo, Jarushka, Markel, Gal, Powell, Nick, Yeung, Sai-Ching J., Sharon, Elad, Dougan, Michael, Wang, Yinghong
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2020
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7030892/
https://ncbi.nlm.nih.gov/pubmed/31800340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01674
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料